Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -11.77 is 238% below its 5-year average of -3.49, near the low end of its 5-year range (-16.06–-0.74).
35.52% below its 12-month average of -8.68.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.92.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 19 comparable quarters.
EARNINGS PER SHARE (EPS)
-11.77
EARNINGS PER SHARE (EPS) AVG TTM
-8.68
EARNINGS PER SHARE (EPS) AVG 3Y
-4.76
EARNINGS PER SHARE (EPS) AVG 5Y
-3.49
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.52%
CURRENT VS 3Y AVG
-147.19%
CURRENT VS 5Y AVG
-237.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lyell Immunopharma, Inc.
Market Cap
$213.57M
Earnings Per Share (EPS)
-11.77
TTM Avg
-8.68
3Y Avg
-4.76
5Y Avg
-3.49
Market Cap
$214.64M
Earnings Per Share (EPS)
-0.79
TTM Avg
-1.48
3Y Avg
-1.81
5Y Avg
-1.82
Market Cap
$212.25M
Earnings Per Share (EPS)
0.19
TTM Avg
0.17
3Y Avg
0.00
5Y Avg
-0.12
Market Cap
$211.58M
Earnings Per Share (EPS)
N/A
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
0.07
Market Cap
$210.64M
Earnings Per Share (EPS)
-2.18
TTM Avg
-1.64
3Y Avg
-1.32
5Y Avg
-1.32
Market Cap
$210.38M
Earnings Per Share (EPS)
0.38
TTM Avg
0.11
3Y Avg
-0.10
5Y Avg
-0.19
Market Cap
$209.44M
Earnings Per Share (EPS)
-3.97
TTM Avg
-0.86
3Y Avg
-1.18
5Y Avg
-1.19
Market Cap
$218.20M
Earnings Per Share (EPS)
-3.22
TTM Avg
-1.33
3Y Avg
-3.00
5Y Avg
-2.91
Market Cap
$208.17M
Earnings Per Share (EPS)
4.12
TTM Avg
3.49
3Y Avg
2.39
5Y Avg
2.00
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $213.57M | -11.77 | -8.68 | -4.76 | -3.49 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | -0.79 | -1.48 | -1.81 | -1.82 |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 0.19 | 0.17 | 0.00 | -0.12 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $211.58M | N/A | 0.11 | 0.08 | 0.07 |
| Sionna Therapeutics, Inc. (SION)vs › | $210.64M | -2.18 | -1.64 | -1.32 | -1.32 |
| Compugen Ltd. (CGEN)vs › | $210.38M | 0.38 | 0.11 | -0.10 | -0.19 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.44M | -3.97 | -0.86 | -1.18 | -1.19 |
| Keros Therapeutics, Inc. (KROS)vs › | $218.20M | -3.22 | -1.33 | -3.00 | -2.91 |
| Pro-Dex, Inc. (PDEX)vs › | $208.17M | 4.12 | 3.49 | 2.39 | 2.00 |
| Profound Medical Corp. (PROF)vs › | $219.30M | -0.99 | -1.25 | -1.31 | -1.33 |
Trailing EPS (TTM)
$-11.77
Forward EPS (Est.)
$-7.23
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -16.06 |
| 2024-12-31 | -1.31 |
| 2023-12-31 | -0.93 |
| 2022-12-31 | -0.74 |
| 2021-12-31 | -1.03 |
| 2020-12-31 | -0.84 |
| 2019-12-31 | -0.53 |
